Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Rheumatology Group, School of Medicine, University Western Australia, Crawley, Western Australia, Australia.
Int J Rheum Dis. 2024 Feb;27(2):e15079. doi: 10.1111/1756-185X.15079.
Given limited regional data, we investigate the state-wide epidemiology, renal and patient outcomes for lupus nephritis (LN) in Western Australia (WA).
Patients hospitalized with incident SLE (≥2 diagnostic codes in the state-wide WA Health Hospital Morbidity Data Collection) in the period 1985-2015 were included (n = 1480). LN was defined by the presence of glomerulonephritis and/or raised serum creatinine. Trends over three study decades for annual incidence rate (AIR)/100.000 population, mortality (MR), and end-stage renal disease (ESRD) rates/100 person years were analyzed by least square regression and compared with a matched control group (n = 12 840).
Clinical evidence of LN developed in 366 SLE patients (25.9%) after a median disease duration of 10 months (IQR 0-101) with renal biopsy performed in 308 (84.2%). The AIR for LN (0.63/100.000) did not change significantly over time (R = .11, p = .85), while point prevalence reached 11.9/100.000 in 2015. ESRD developed in 14.1% (n = 54) of LN patients vs. 0.2% in non-LN SLE patients and 0.05% in controls (all p ≤ 0.01). ESRD rates increased over time in LN patients (0.4 to 0.7, R = .52, p = .26). The odds ratio for death was 8.81 (CI 3.78-22.9) for LN and 6.62 (CI 2.76-17.9) for non-LN SLE patients compared to controls and MR for LN patients increased over time (1.3 to 2.2, R = .84, p = .26).
The incidence rate of LN in WA remained unchanged over 30 years. A lack of improvement in renal failure and mortality rates illustrates the pressing need for better long-term treatment options and/or strategies in LN.
鉴于区域数据有限,我们研究了西澳大利亚州(WA)狼疮肾炎(LN)的全州流行病学、肾脏和患者结局。
纳入了 1985 年至 2015 年期间在全州 WA 健康医院发病率数据收集中出现的首发 SLE(≥2 个诊断代码)住院患者(n=1480)。LN 通过肾小球肾炎和/或血清肌酐升高来定义。通过最小二乘回归分析了 30 年三个研究十年期间的年发病率(AIR)/每 100000 人、死亡率(MR)和终末期肾病(ESRD)率/每 100 人年,并与匹配的对照组(n=12840)进行了比较。
在中位疾病持续时间 10 个月(IQR 0-101)后,366 例 SLE 患者(25.9%)出现了 LN 的临床证据,其中 308 例(84.2%)进行了肾活检。LN 的 AIR(0.63/100000)随时间变化无明显变化(R = .11,p = .85),而 2015 年的时点患病率达到了 11.9/100000。LN 患者中 ESRD 的发生率为 14.1%(n = 54),而非 LN SLE 患者为 0.2%,对照组为 0.05%(均 p ≤ 0.01)。LN 患者的 ESRD 发生率随时间增加(0.4 至 0.7,R =.52,p = .26)。与对照组相比,LN 患者的死亡风险比为 8.81(CI 3.78-22.9),非 LN SLE 患者为 6.62(CI 2.76-17.9),LN 患者的 MR 随时间增加(1.3 至 2.2,R =.84,p = .26)。
WA 30 年来 LN 的发病率保持不变。肾功能衰竭和死亡率改善情况不佳表明,LN 迫切需要更好的长期治疗选择和/或策略。